Physician profile
Jennifer Speaker
NPI 1699745166
$9,656.97
in general payments reported to CMS, 2019-2025
44 companies · $1,709 in 2025
The $1,709 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,388 · 2020: $978 · 2021: $1,050 · 2022: $978 · 2023: $1,641 · 2024: $1,914 · 2025: $1,709.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,133 · Education: $132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,132.51 |
| Education | $131.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,627.21 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,178.75 | 2019-2025 | Jardiance |
| Abbvie INC. | $842.39 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $727.19 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $615.00 | 2019-2025 | |
| Lilly USA, LLC | $588.30 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $437.89 | 2019-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $381.23 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Dexcom, INC. | $299.71 | 2022-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $280.47 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $275.35 | 2021-2025 | |
| Amgen INC. | $243.64 | 2019-2024 | Repatha, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $221.16 | 2020-2024 | Trintellix |
| Allergan, INC. | $210.88 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $194.06 | 2019-2023 | Xarelto |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Speaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.